An imaging flow cytometry apparatus and method which allows registering multiple locations across a cell, and/or across multiple flow channels, in parallel using radio-frequency-tagged emission (FIRE) coupled with a parallel optical detection scheme toward increasing analysis throughput. An optical source is modulated by multiple RF frequencies to produce an optical interrogation beam having a spatially distributed beat frequency. This beam is directed to one or more focused streams of cells whose responsive fluorescence, in different frequencies, is registered in parallel by an optical detector.

The present invention relates to compositions comprising magnetic particles, the methods of using these compositions in processing animal sperm, the resulting sperm and embryo products, and the methods of use of these compositions to increase the efficiency, efficacy and/or speed of cell processing and artificial insemination techniques.

A method generates a natural immunity to a pathogen in the absence of a vaccine. The process draws a blood sample, exposes the blood sample to a pathogen outside of a living organism, and measures the antibody type, level, and a pathogen level in the exposed blood sample. The method injects the blood sample exposed to the pathogen into the source of the blood sample when one or more antibody types are detected at a predetermined level and the pathogen level is below a predetermined level.

A method generates a natural immunity to a pathogen in the absence of a vaccine. The process draws a blood sample, exposes the blood sample to a pathogen outside of a living organism, and measures the antibody type, level, and a pathogen level in the exposed blood sample. The method injects the blood sample exposed to the pathogen into the source of the blood sample when one or more antibody types are detected at a predetermined level and the pathogen level is below a predetermined level.

A method of screening an antibody comprises preparing a serum having a target antibody and a non-target antibody; providing the serum with a first antigen that specifically binds the target antibody to obtain a first mixture; selectively obtaining the first conjugate by separating the first conjugate from the non-target antibody in the first mixture; dissociating the first conjugate, and a redundant non-target antibody adsorbed to the first conjugate into the first antigen, the target antibody and the redundant non-target antibody; removing the first antigen to obtain a second mixture of the target antibody and the redundant non-target antibody; providing the second mixture with a second antigen to form a second conjugate, so that third mixture including the target antibody and the second conjugate may be obtained; and selectively obtaining a target antibody by separating the second conjugate from the target antibody in the third mixture.

A method of screening an antibody comprises preparing a serum having a target antibody and a non-target antibody; providing the serum with a first antigen that specifically binds the target antibody to obtain a first mixture; selectively obtaining the first conjugate by separating the first conjugate from the non-target antibody in the first mixture; dissociating the first conjugate, and a redundant non-target antibody adsorbed to the first conjugate into the first antigen, the target antibody and the redundant non-target antibody; removing the first antigen to obtain a second mixture of the target antibody and the redundant non-target antibody; providing the second mixture with a second antigen to form a second conjugate, so that third mixture including the target antibody and the second conjugate may be obtained; and selectively obtaining a target antibody by separating the second conjugate from the target antibody in the third mixture.

A cell analysis device includes a determination target identifier extraction portion configured to extract a determination target identifier that is information indicating an identification substance associated with a determination target cell that is a cell of a determination target from a table indicating a corresponding relationship between the cell and the identification substance for each compartment with respect to compartments flowing along a flow path including the cell and the identification substance that is a substance associated with the cell, an identifier acquisition portion configured to acquire the identifier that is the information for identifying the identification substance included in the compartments flowing along the flow path, a determination portion configured to determine a compartment including the determination target cell among the compartments flowing along the flow path on the basis of the identifier acquired by the identifier acquisition portion and the determination target identifier extracted by the determination target identifier extraction portion, and an output portion configured to output a determination result of the determination portion.

The Invention provides a method of immunopurifying and characterising an analyte from a sample comprising: (i) providing a predetermined amount of a control substance bound to a substrate via a linkage cleavable by acidic pH and/or reducing agents and optionally additional analyte specific antibodies or fragments thereof bound to a substrate, wherein the control substance is specific for the analyte or is not specific for the analyte; (ii) allowing analyte when present in the sample to bind to the control substance or said optional additional analyte-specific antibodies or fragments, wherein the control substance bound to the substrate (i) may be provided after contacting the analyte with the optional additional analyte-specific antibodies (ii); (iii) washing unbound material away from the substrate; (iv) acid eluting the analyte bound thereto, from at least one substrate; (v) performing mass spectrometry to identify two or more peaks, at least one peak of which is associated with the presence of the analyte and at least a second peak which is associated with at least a portion of the control substance; and (vi) comparing the size or intensity of the second peak to a predetermined calibration value to allow the first peak associated with the analyte to be calibrated.

Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.

Assays and methods for verifying the validity of a urine sample submitted for Drugs of Abuse (DOA) testing. Embodiments include a SUD Diagnostic Panel that includes six assays: specific gravity index assay, long-duration counterfeit urine assay, short-duration counterfeit urine assay, oxidant history assay, pH assay, and creatinine assay. The SUD Diagnostic Panel detects twelve principle classes of adulteration. Detection of adulteration of one or more urine samples from a patient indicates an attempt to subvert test results and provides an objective indication in one instance and an object diagnosis in another instance of SUD.